On March 19, 2025 TwoStep Therapeutics, a biotechnology company developing innovative, first-in-class, multispecific targeted peptide conjugate therapies for solid tumors, reported its debut public scientific presentation on March 27, 2025, at the 4th Novel Conjugates Summit taking place in Boston, Massachusetts (Press release, TwoStep Therapeutics, MAR 19, 2025, View Source [SID1234651276]). This presentation will highlight the outstanding preclinical efficacy and safety of its lead tumor-targeted drug conjugate program, along with a first look at their new radiopharmaceutical program.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation:
Title: Overcoming Tumor Heterogeneity via Multispecific Targeting
Date and Time: Thursday, March 27, 2025, at 9:00 a.m. ET
Invited Speaker: Caitlyn Miller, PhD, Co-Founder & CEO of TwoStep Therapeutics

TwoStep Therapeutics is a Stanford University spin-out launched in 2024, co-founded by Nobel Prize winner Carolyn Bertozzi, Jennifer Cochran, Ron Levy, and Caitlyn Miller, with seed investment of $8.7M to date.

"The company has made tremendous progress since our launch, and we’re excited to share our advancements at this summit," said Caitlyn Miller, CEO of TwoStep Therapeutics. "This event provides an excellent opportunity to highlight our innovative research and explore potential partnerships to further our mission of developing effective cancer therapies."